<i id='D065CA0D35'><strike id='D065CA0D35'><tt id='D065CA0D35'><pre id='D065CA0D35'></pre></tt></strike></i> 
EQRx is done, sold for its cash.
The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.
advertisement
The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTED Log In
Virginia high school admissions case could be legal follow 
EpiPen alternative approval delay highlights citizen petition issue 
United colonoscopy coverage change 'may cost lives,' doctors say 
Drug for rare kidney disease narrowly misses mark in clinical trial 
Anesthesiologist group: stop taking Ozempic before surgery 
CDC advisers recommend seasonal use of Pfizer RSV shot 
Medicare details structure of new drug price negotiation program 
Biden targets hefty hospital 'facility fees' that often surprise patients 
ChatGPT in medicine: STAT answers readers' burning questions
Biden targets hefty hospital 'facility fees' that often surprise patients 
Hepatitis C has a cure — but many Americans still lack access to it 
Readout LOUD podcast: possible new ALS drug, artificial wombs 
State Dept. review finds Biden bears some blame for Afghanistan failures 
Senators: Long 
Apple is now the first public company to be valued at $3 trillion 
